Studying the role of Interleukin-6 (IL-6) and C-reactive protein (CRP) in Patients Infected with COVID-19 until Recovery

Background: Researchers studying medicine are becoming concerned about the pathogen's deciding element as the coronavirus illness 2019 (COVID-19) expands globally. We postulated a relationship between the degree of viral recovery and the amount of interleukin 6 with C-reactive protein. Aim: Study the level of Interleukin-6 in the case of infection with COVID-19 with C-reactive protein and compare its level in the case of response and non-response to treatment. Results: The current study included 1,100 people who had symptoms of the common cold and were tested for the presence of SARS-2 RNA using reverse transcriptase-polymerase chain reaction (RT-PCR). 660 cases came back positive, and all cases underwent laboratory tests. Out of 660 patients, 50 patients were selected. Patients with COVID-19 infection and 50 people without COVID-19 infection were randomly assigned to study interleukin and C-RP levels in these patients. Our results showed that there are high statistical significances (P. value < 0.05) in the level of IL-6 and the level of C-RP between patients infected with COVID-19 before and after treatment, and there are also high statistical significances (P. value < 0.05) between patients who responded and those who did not respond to treatment. Conclusion: Il-6 and C-RP levels increase during COVID-19 infection and gradually decrease with treatment until complete recovery. In particular, the levels of Il-6 and C-RP increased significantly in patients who did not respond to treatment, while they decreased in patients who responded to treatment